[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0515581A - métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer - Google Patents

métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer

Info

Publication number
BRPI0515581A
BRPI0515581A BRPI0515581-9A BRPI0515581A BRPI0515581A BR PI0515581 A BRPI0515581 A BR PI0515581A BR PI0515581 A BRPI0515581 A BR PI0515581A BR PI0515581 A BRPI0515581 A BR PI0515581A
Authority
BR
Brazil
Prior art keywords
computer program
methods
optimization
analysis
products
Prior art date
Application number
BRPI0515581-9A
Other languages
English (en)
Inventor
Raphael Marcelpoil
Clark Merrill Whitehead
Timothy J Fischer
Original Assignee
Tripath Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripath Imaging Inc filed Critical Tripath Imaging Inc
Publication of BRPI0515581A publication Critical patent/BRPI0515581A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

"MéTODOS E PRODUTOS DE PROGRAMA DE COMPUTADOR PARA ANáLISE E OTIMIZAçãO DE CANDIDATOS MARCADORES PARA PROGNóSTICO DE CáNCER". Métodos e produtos de programa de computador para avaliação de e otimização de um ou mais marcadores para uso no estabelecimento de um prognóstico para um paciente sofrendo de uma doença são proporcionados. Mais particularmente, os métodos incluem etapas para avaliação sistemática de uma série de características que podem ser extraídas de uma imagem de uma amostra corporal, tal como uma lâmina histológica, que tenha sido esposta a um ou mais biomarcadores, de modo a estabelecer uma regra de decisão prognóstica baseado em uma ou mais das características extraídas, de modo que a regra de decisão proporciona um prognóstico que é otimamente previsível da expectativa real para o paciente. Assim, os método e produtos de programa de computador proporcionados fornecem prognósticos otimamente previsíveis para auxiliar os médicos a desenvolver estratégias para tratamento eficaz do paciente.
BRPI0515581-9A 2004-09-22 2005-09-22 métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer BRPI0515581A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61196504P 2004-09-22 2004-09-22
US61207304P 2004-09-22 2004-09-22
PCT/US2005/033931 WO2006036726A1 (en) 2004-09-22 2005-09-22 Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis

Publications (1)

Publication Number Publication Date
BRPI0515581A true BRPI0515581A (pt) 2008-07-29

Family

ID=35695736

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0515581-9A BRPI0515581A (pt) 2004-09-22 2005-09-22 métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer
BRPI0515562-2A BRPI0515562A (pt) 2004-09-22 2005-09-22 métodos e composições para avaliação do prognóstico do cáncer de mama

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0515562-2A BRPI0515562A (pt) 2004-09-22 2005-09-22 métodos e composições para avaliação do prognóstico do cáncer de mama

Country Status (11)

Country Link
US (3) US20060063190A1 (pt)
EP (2) EP1800130B1 (pt)
JP (2) JP2008513032A (pt)
KR (2) KR20070061893A (pt)
AT (1) ATE520988T1 (pt)
AU (2) AU2005289728B2 (pt)
BR (2) BRPI0515581A (pt)
CA (2) CA2580937C (pt)
IL (2) IL182063A0 (pt)
MX (1) MX2007003502A (pt)
WO (2) WO2006036788A2 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8594410B2 (en) * 2006-08-28 2013-11-26 Definiens Ag Context driven image mining to generate image-based biomarkers
US20050112622A1 (en) 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
CN101484806A (zh) 2006-05-17 2009-07-15 协乐民公司 一种对组织进行自动分析的方法
KR100786759B1 (ko) * 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
JP2010500577A (ja) * 2006-08-07 2010-01-07 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 癌の予後および予測シグナチャーのプロテオミクスパターン
US8697373B2 (en) 2006-10-06 2014-04-15 Clarient Diagnostic Services, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
ES2374686T3 (es) 2007-05-14 2012-02-21 Historx, Inc. Separación en compartimentos por caracterización de píxel usando agrupamiento de datos de imágenes.
JP5593221B2 (ja) * 2007-06-15 2014-09-17 ヒストロックス，インコーポレイテッド． 顕微鏡機器を標準化するための方法およびシステム
US20100221722A1 (en) * 2007-06-15 2010-09-02 University Of North Carolina At Chapel Hill Methods for evaluating breast cancer prognosis
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) * 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
US7978258B2 (en) * 2007-08-31 2011-07-12 Historx, Inc. Automatic exposure time selection for imaging tissue
EP2034027A1 (en) * 2007-09-04 2009-03-11 Siemens Healthcare Diagnostics GmbH Molecular markers to predict response to chemotherapy and EGFR family inhibiton by targeted strategies
CA2696947A1 (en) * 2007-09-07 2009-03-12 Universite Libre De Bruxelles Methods and tools for prognosis of cancer in er- patients
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
WO2009055480A2 (en) * 2007-10-22 2009-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tgf-beta gene expression signature in cancer prognosis
WO2009089521A2 (en) * 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
BRPI0914734A2 (pt) * 2008-06-26 2015-10-20 Dana Farber Cancer Inst Inc assinaturas e determinantes associados com metástase e métodos de uso dos mesmos
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
ES2573945T3 (es) 2008-09-16 2016-06-13 Novartis Ag Cuantificación reproducible de expresión de biomarcadores
US20100124747A1 (en) * 2008-11-03 2010-05-20 University Of Southern California Compositions and methods for diagnosis or prognosis of testicular cancer
US20100120080A1 (en) * 2008-11-03 2010-05-13 Quest Diagnostics Investments Incorporated Cancer diagnosis using ki-67
KR101141103B1 (ko) * 2009-12-15 2012-05-02 계명대학교 산학협력단 임상진단 결정 규칙 생성 방법
UA110790C2 (uk) * 2010-03-31 2016-02-25 Сівідон Діагностікс Гмбх Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні
US20120003639A1 (en) * 2010-04-27 2012-01-05 Prelude, Inc. Cancer biomarkers and methods of use thereof
BR112012030625A2 (pt) 2010-06-03 2017-06-27 Pharmacyclics Inc uso de inibidores de tirosina quinase de bruton (btk)
US9129426B2 (en) 2010-08-31 2015-09-08 General Electric Company Motion compensation in image processing
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images
CA2830501C (en) 2011-03-17 2023-10-17 Cernostics, Inc. Systems and compositions for diagnosing barrett's esophagus and methods of using the same
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
WO2013089882A2 (en) * 2011-09-27 2013-06-20 The Regents Of The University Of Michigan Recurrent gene fusions in breast cancer
WO2013067198A1 (en) * 2011-11-01 2013-05-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene signature for the prediction of nf-kappab activity
EP2773390B1 (en) * 2011-11-03 2020-12-30 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
US8885912B2 (en) * 2011-11-03 2014-11-11 General Electric Company Generate percentage of positive cells for biomarkers by normalizing and autothresholding the image intensity produced by immunohistochemistry technique
CN104662166A (zh) * 2012-04-20 2015-05-27 纪念斯隆-凯特琳癌症中心 与转移性乳腺癌相关的基因表达图谱
US8737709B2 (en) * 2012-04-30 2014-05-27 General Electric Company Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue
JP6317732B2 (ja) * 2012-04-30 2018-04-25 ゼネラル・エレクトリック・カンパニイ 生物組織に対するバイオマーカーの品質レビュースコアリング及び画像解析方法を実行するためのシステム並びに方法
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
US20150212087A1 (en) * 2012-07-27 2015-07-30 Centre Leon Berard Detection of the ERalpha/Src/PI3K Complex as Predictive Marker in Breast Cancer
JP2014123230A (ja) * 2012-12-20 2014-07-03 Sony Corp 画像処理装置、画像処理方法、及び、プログラム
CN103136333B (zh) * 2013-01-29 2016-08-10 冯力新 一种抽象属性的量化评价分析方法
CN103293321B (zh) * 2013-05-27 2015-05-13 北京大学 一种检测dna损伤诱导的早期核仁应激的试剂盒及其应用
EP3033079B1 (en) 2013-08-12 2018-10-31 Pharmacyclics LLC Methods for the treatment of her2 amplified cancer
US9519823B2 (en) * 2013-10-04 2016-12-13 The University Of Manchester Biomarker method
US9953417B2 (en) 2013-10-04 2018-04-24 The University Of Manchester Biomarker method
US9785752B1 (en) * 2014-02-25 2017-10-10 Flagship Biosciences, Inc. Method for stratifying and selecting candidates for receiving a specific therapeutic approach
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US20170176440A1 (en) * 2014-03-27 2017-06-22 The Board Of Regents Of The University Of Texas System Methods and compositions for evaluating breast cancer patients
EP3155592B1 (en) 2014-06-10 2019-09-11 Leland Stanford Junior University Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides
KR20170084086A (ko) 2014-11-17 2017-07-19 아르노 테라퓨틱스 인코포레이티드 오나프리스톤 연장-방출 조성물 및 방법
EP3227687A4 (en) 2014-12-05 2018-10-24 Prelude, Inc. Dcis recurrence and invasive breast cancer
US20180040120A1 (en) * 2014-12-29 2018-02-08 Flagship Biosciences, Inc. Methods for quantitative assessment of mononuclear cells in muscle tissue sections
KR101765999B1 (ko) 2015-01-21 2017-08-08 서울대학교산학협력단 암 바이오마커의 성능 평가 장치 및 방법
WO2016123525A1 (en) * 2015-01-30 2016-08-04 Raytheon Company Apparatus and methods for classifying and counting corn kernels
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
EP3786640B1 (en) 2015-11-25 2022-08-24 Cernostics, Inc. Methods of detecting malignant transformation of barrett's esophagus
CA3007292A1 (en) * 2015-12-02 2017-06-08 Clearlight Diagnostics Llc Methods for preparing and analyzing tumor tissue samples for detection and monitoring of cancers
AU2016370499B2 (en) 2015-12-15 2022-06-30 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
CA3013926A1 (en) 2016-02-08 2017-08-17 Imago Systems, Inc. System and method for the visualization and characterization of objects in images
DK3430022T3 (da) 2016-03-14 2020-05-18 Somalogic Inc Forbindelser og fremgangsmåder til syntese af 5-(N-beskyttet-tryptaminocarboxyamid)-2'-deoxyuridin-phosphoramidit til inkorporering i en nukleinsyresekvens
EP3430384A4 (en) * 2016-03-14 2019-07-31 Proteocyte Diagnostics Inc. AUTOMATED METHOD FOR THE ASSESSMENT OF CANCER RISK BY TISSUE SAMPLES AND SYSTEM THEREFOR
JP2019515265A (ja) * 2016-04-20 2019-06-06 エーザイ インク． バイオマーカーを使用する漿液性卵巣がんの予後
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
JP2020533039A (ja) 2017-08-07 2020-11-19 イマーゴ・システムズ，インコーポレーテッド 画像中の物体の視覚化および特徴づけのためのシステムおよび方法
JP2022500504A (ja) 2018-09-14 2022-01-04 プレリュード コーポレーションPrelude Corporation 浸潤性乳癌のリスクを有する対象の治療の選択方法
WO2020124084A1 (en) * 2018-12-15 2020-06-18 The Brigham And Women's Hospital, Inc. Augmented digital microscopy for lesion analysis
CA3186353A1 (en) 2020-07-17 2022-01-20 Bastian LINDER Prognostic biomarkers for cancer
WO2024148280A1 (en) 2023-01-06 2024-07-11 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parc inhibitor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1994000591A1 (en) * 1992-06-26 1994-01-06 Nippon Shinyaku Co., Ltd. Monoclonal antibody, production process, antibody-producing cell, and diagnostic method
EP0745243B9 (en) * 1994-02-14 2008-01-02 AutoCyte North Carolina LLC Automated cytological specimen classification methods
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
WO1998008439A1 (en) * 1996-08-25 1998-03-05 Sensar, Inc. Apparatus for the iris acquiring images
US5798266A (en) * 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
JP2001504233A (ja) * 1996-11-22 2001-03-27 シルーヴ メディカル テクノロジーズ リミテッド 癌を有する被験者の早期検出のための全血／マイトジェンアッセイおよびキット
JP5213202B2 (ja) * 1998-10-28 2013-06-19 バイシス・インコーポレーテツド 細胞アレイならびに遺伝障害マーカーの検出および使用方法
AU2876900A (en) * 1999-02-10 2000-08-29 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids andmethods of use
WO2000055629A2 (en) * 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Methods of diagnosing and treating breast cancer
US6642009B2 (en) * 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
AU781992B2 (en) * 2000-04-04 2005-06-23 Medical Research Council Methods involving induced dimerisation by cellular components
IL152428A0 (en) * 2000-04-26 2003-05-29 Univ Kingston Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
GB0011439D0 (en) * 2000-05-12 2000-06-28 Novartis Res Found Cancer diagnosis and assays for screening
WO2002008765A2 (en) * 2000-07-26 2002-01-31 Stanford University Basal cell markers in breast cancer and uses thereof
US6703204B1 (en) * 2000-07-28 2004-03-09 The Brigham & Women's Hospital, Inc. Prognostic classification of breast cancer through determination of nucleic acid sequence expression
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
WO2002103320A2 (en) * 2001-06-18 2002-12-27 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
JP3721105B2 (ja) * 2001-08-22 2005-11-30 日本電気株式会社 組織検査法を利用する胃癌の切除手術後の予後検査方法
US7065236B2 (en) * 2001-09-19 2006-06-20 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
US6855554B2 (en) * 2001-09-21 2005-02-15 Board Of Regents, The University Of Texas Systems Methods and compositions for detection of breast cancer
US20040002067A1 (en) * 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US7133547B2 (en) * 2002-01-24 2006-11-07 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
AU2003217397A1 (en) * 2002-02-14 2003-09-04 The Johns Hopkins University School Of Medecine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040229299A1 (en) * 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2521077A1 (en) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Erbb surface receptor complexes as biomarkers
KR20180050427A (ko) * 2003-11-17 2018-05-14 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
EP1704416A2 (en) * 2004-01-16 2006-09-27 Ipsogen Protein expression profiling and breast cancer prognosis
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
CA2560782C (en) * 2004-03-24 2013-05-21 Tripath Imaging, Inc. Methods and compositions for the detection of cervical disease

Also Published As

Publication number Publication date
JP5184087B2 (ja) 2013-04-17
AU2005289756A1 (en) 2006-04-06
WO2006036788A2 (en) 2006-04-06
EP1805676A1 (en) 2007-07-11
IL182062A0 (en) 2007-07-24
ATE520988T1 (de) 2011-09-15
US7899623B2 (en) 2011-03-01
JP2008513032A (ja) 2008-05-01
US20090269856A1 (en) 2009-10-29
KR20070068401A (ko) 2007-06-29
AU2005289728B2 (en) 2011-11-24
BRPI0515562A (pt) 2008-07-29
EP1800130A2 (en) 2007-06-27
WO2006036788A3 (en) 2006-08-17
IL182063A0 (en) 2008-04-13
CA2580937A1 (en) 2006-04-06
MX2007003502A (es) 2007-10-10
AU2005289728A1 (en) 2006-04-06
CA2580937C (en) 2016-02-02
KR20070061893A (ko) 2007-06-14
WO2006036726A1 (en) 2006-04-06
CA2580795A1 (en) 2006-04-06
AU2005289756B2 (en) 2011-10-13
EP1800130B1 (en) 2011-08-17
JP2008513793A (ja) 2008-05-01
US20060063190A1 (en) 2006-03-23
US20060078926A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
BRPI0515581A (pt) métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer
Cullen et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low-and intermediate-risk prostate cancer
MY150234A (en) Predictive markers for ovarian cancer
Lotan et al. Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors
Mahar et al. Critical assessment of clinical prognostic tools in melanoma
Gallina et al. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy
Peng et al. An expression signature at diagnosis to estimate prostate cancer patients’ overall survival
DE602005019294D1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
Van den Broeck et al. Validation of the Decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery
Ravvaz et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in a United States population
Lund et al. Systems epidemiology in cancer
BR112022004094A2 (pt) Biomarcadores para predizer atividade de doença de esclerose múltipla
Saldanha et al. 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma
WO2005100999A3 (en) Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
Sonpavde et al. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy
CN105705653A (zh) 针对膀胱癌的dna甲基化生物标志物
Duangkumpha et al. Discovery and qualification of serum protein biomarker candidates for cholangiocarcinoma diagnosis
Wong et al. International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy
Zeng et al. Development and external validation of a nomogram predicting prognosis of upper tract urothelial carcinoma after radical nephroureterectomy
Patel et al. Subtyping the risk of intermediate risk prostate cancer for active surveillance based on adverse pathology at radical prostatectomy
Ibrahim et al. Artificial intelligence-based mitosis scoring in breast cancer: Clinical application
MXPA06012232A (es) Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas.
Zheng et al. Application of nomograms to predict overall and cancer-specific survival in patients with chordoma
Vesely et al. Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome
KR20160088663A (ko) 질병 관련 유전자 탐색 장치 및 그 방법

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.